SAN DIEGO, CA USA (UroToday.com) - The main objectives of this study were to examine the incidence of bladder cancer following radiation therapy for uterine cancer and to determine if the incidence, morbidity, and mortality are sufficient to justify an organized attempt to look for hematuria and screen these patients closer.
Data for this study was obtained from the Surveillance, Epidemiology and End-Results (SEER) program's Multiple Primary-Standardized Incidence Ratio (MP-SIR) database. Women diagnosed with localized or regionally-advanced uterine cancer as their first primary malignancy during years 1980-2005 were included in the analysis, and comparisons were made between those treated with no RT, EBRT only, EBRT+BT, and EBRT +/- BT. A total of 343 incident BC cases were recorded. The total number with no RT was 40 955, of whom 197 developed BC. The total number with EBRT+/-BT, was 15 726, 146 developed BC -- a statistically significant difference, p-value < 0.0001. Adjusted incidence rate of BC after any RT was 10.1 (95% CI: 8.2-11.9), without RT the rate was 5.8 (95% CI: 4.9-6.6). Adjusted rate ratio of BC after any RT was 1.7(95% CI: 1.4-2.2) times greater than the rate observed in the absence of RT. Fatal BC after any RT was 2.3(95% CI: 1.4-3.8) times greater than the rate observed in the absence of RT.
Given this data, women with history of XRT for treatment of GYN-related oncology are at higher risk of developing bladder cancer. Micro-hematuria and gross hematuria in this subset of patients should prompt a referral and further evaluation by a urologist.
Presented by Janet Baack Kukreja, Emelian Scosyrev, Edward Messing, and Guan Wu at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA
Reported for UroToday.com by Reza Mehrazin, MD
